The atrial fibrillation conundrum in dialysis patients

American Heart Journal

Volumn 174, Issue , 2016, Pages 111-119

  De Vriese, An S ^a   Caluwé, Rogier ^b   Raggi, Paolo ^c  

^a Division of Nephrology and Infectious Diseases   (Belgium)

^b OLV HOSPITAL   (Belgium)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

ATRIAL FIBRILLATION; BLEEDING; BLOOD VESSEL CALCIFICATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; HEART ATRIUM APPENDAGE; HEMODIALYSIS PATIENT; HUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); COMPLICATION; HEALTH; KIDNEY FAILURE, CHRONIC; MORBIDITY; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; SURVIVAL RATE; TRENDS;

ATRIAL FIBRILLATION; GLOBAL HEALTH; HUMANS; KIDNEY FAILURE, CHRONIC; MORBIDITY; RENAL DIALYSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84977541329     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.01.010     Document Type: Review

References (69)

1. [1] Goldstein, B.A., Arce, C.M., Hlatky, M.A., et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation 126:19 (2012), 2293–2301.
2. [2] January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:21 (2014), e1–e76.
3. [3] Zimmerman, D., Sood, M.M., Rigatto, C., et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 27:10 (2012), 3816–3822.
4. [4] Wizemann, V., Tong, L., Satayathum, S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 77:12 (2010), 1098–1106.
5. [5] Piccini, J.P., Hammill, B.G., Sinner, M.F., et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes 5:1 (2012), 85–93.
6. [6] Bansal, N., Fan, D., Hsu, C.Y., et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127:5 (2013), 569–574.
7. [7] Buiten, M.S., de Bie, M.K., Rotmans, J.I., et al. The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart 100:9 (2014), 685–690.
8. [8] Genovesi, S., Vincenti, A., Severi, S., Insights into intradialytic atrial fibrillation onset mechanisms. Heart, 100(16), 2014, 1302.
9. [9] Herrington, W., Haynes, R., Staplin, N., et al. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial 28:1 (2015), 35–47.
10. [10] Findlay, M.D., Thomson, P.C., Fulton, R.L., et al. Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke 46:9 (2015), 2477–2481.
11. [11] Bonde, A.N., Lip, G.Y., Kamper, A.L., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 64:23 (2014), 2471–2482.
12. [12] Sood, M.M., Larkina, M., Thumma, J.R., et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int 84:3 (2013), 600–608.
13. [13] Chao, T.F., Liu, C.J., Wang, K.L., et al. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. Heart Rhythm 11:10 (2014), 1752–1759.
14. [14] Shen, J.I., Montez-Rath, M.E., Lenihan, C.R., et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis 66:4 (2015), 677–688.
15. [15] Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:12 (2007), 857–867.
16. [16] Hart, R.G., Pearce, L.A., Asinger, R.W., et al. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol 6:11 (2011), 2599–2604.
17. [17] Olesen, J.B., Lip, G.Y., Kamper, A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367:7 (2012), 625–635.
18. [18] Carrero, J.J., Evans, M., Szummer, K., et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 311:9 (2014), 919–928.
19. [19] Winkelmayer, W.C., Liu, J., Setoguchi, S., et al. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 6:11 (2011), 2662–2668.
20. [20] Wakasugi, M., Kazama, J.J., Tokumoto, A., et al. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin Exp Nephrol 18:4 (2014), 662–669.
21. [21] Shah, M., Avgil Tsadok, M., Jackevicius, C.A., et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 129:11 (2014), 1196–1203.
22. [22] Genovesi, S., Rossi, E., Gallieni, M., et al. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant 30:3 (2015), 491–498.
23. [23] Chan, K.E., Lazarus, J.M., Thadhani, R., et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20:10 (2009), 2223–2233.
24. [24] Li, J., Wang, L., Hu, J., et al. Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis 25:8 (2015), 706–713.
25. [25] Chan, P.H., Huang, D., Yip, P.S., et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace, 2015 [pii: euv289. Epub ahead of print].
26. [26] Lenihan, C.R., Montez-Rath, M.E., Shen, J.I., et al. Correlates and outcomes of warfarin initiation in kidney transplant recipients newly diagnosed with atrial fibrillation. Nephrol Dial Transplant 30:2 (2015), 321–329.
27. [27] Hylek, E.M., Go, A.S., Chang, Y., et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 349:11 (2003), 1019–1026.
28. [28] Knoll, F., Sturm, G., Lamina, C., et al. Coumarins and survival in incident dialysis patients. Nephrol Dial Transplant 27:1 (2012), 332–337.
29. [29] Palareti, G., Cosmi, B., Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost 102:2 (2009), 268–278.
30. [30] Dzeshka, M.S., Lane, D.A., Lip, G.Y., Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2 -VASc, R2 CHADS2, HAS-BLED, ATRIA, and more). Clin Cardiol 37:10 (2014), 634–644.
31. [31] O'Brien, E.C., Simon, D.N., Thomas, L.E., et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 36:46 (2015), 3258–3264.
32. [32] Roskell, N.S., Samuel, M., Noack, H., et al. Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies. Europace 15:6 (2013), 787–797.
33. [33] Holden, R.M., Harman, G.J., Wang, M., et al. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 3:1 (2008), 105–110.
34. [34] Limdi, N.A., Beasley, T.M., Baird, M.F., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20:4 (2009), 912–921.
35. [35] Sood, M.M., Rigatto, C., Bueti, J., et al. Thrice weekly warfarin administration in haemodialysis patients. Nephrol Dial Transplant 24:10 (2009), 3162–3167.
36. [36] Brodsky, S.V., Nadasdy, T., Rovin, B.H., et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 80:2 (2011), 181–189.
37. [37] Böhm, M., Ezekowitz, M.D., Connolly, S.J., et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 65:23 (2015), 2481–2493.
38. [38] Raggi, P., Boulay, A., Chasan-Taber, S., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J Am Coll Cardiol 39:4 (2002), 695–701.
39. [39] Raggi, P., Bellasi, A., Gamboa, C., et al. All-cause mortality in hemodialysis patients with heart valve calcification. Clin J Am Soc Nephrol 6:8 (2011), 1990–1995.
40. [40] Bellasi, A., Raggi, P., Vascular imaging in chronic kidney disease. Curr Opin Nephrol Hypertens 21:4 (2012), 382–388.
41. [41] Zoccali, C., London, G., Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transplant 30:3 (2015), 352–357.
42. [42] Movva, R., Murthy, K., Romero-Corral, A., et al. Calcification of the mitral valve and annulus: systematic evaluation of effects on valve anatomy and function. J Am Soc Echocardiogr 26:10 (2013), 1135–1142.
43. [43] Bover, J., Evenepoel, P., Ureña-Torres, P., et al. CKD-MBD Working Group of ERA-EDTA. Pro: cardiovascular calcifications are clinically relevant. Nephrol Dial Transplant 30:3 (2015), 345–351.
44. [44] Chatrou, M.L., Winckers, K., Hackeng, T.M., et al. Vascular calcification: the price to pay for anticoagulation therapy with vitamin K–antagonists. Blood Rev 26:4 (2012), 155–166.
45. [45] Beazley, K.E., Deasey, S., Lima, F., et al. Transglutaminase 2-mediated activation of â-catenin signaling has a critical role in warfarin-induced vascular calcification. Arterioscler Thromb Vasc Biol 32:1 (2012), 123–130.
46. [46] Kaesler, N., Magdeleyns, E., Herfs, M., et al. Impaired vitamin K recycling in uremia is rescued by vitamin K supplementation. Kidney Int 86:2 (2014), 286–293.
47. [47] Tantisattamo, E., Han, K.H., O'Neill, W.C., Increased vascular calcification in patients receiving warfarin. Arterioscler Thromb Vasc Biol 35:1 (2015), 237–242.
48. [48] Mac-Way, F., Poulin, A., Utescu, M.S., et al. The impact of warfarin on the rate of progression of aortic stiffness in hemodialysis patients: a longitudinal study. Nephrol Dial Transplant 29:11 (2014), 2113–2120.
49. [49] K/DOQI Workgroup, K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45:4 Suppl 3 (2005), S1–S153.
50. [50] Herzog, C.A., Asinger, R.W., Berger, A.K., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80:6 (2011), 572–586.
51. [51] Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:21 (2012), 2719–2747.
52. [52] Verma, A., Cairns, J.A., Mitchell, L.B., et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 30:10 (2014), 1114–1130.
53. [53] Juma, S., Thomson, B.K., Lok, C.E., et al. Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty. BMC Nephrol, 14, 2013, 174.
54. [54] Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:9921 (2014), 955–962.
55. [55] Eikelboom, J.W., Connolly, S.J., Brueckmann, M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med, 369(13), 2013, 1206.
56. [56] Connolly, S.J., Eikelboom, J., Dorian, P., et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J 34:20 (2013), 1498–1505.
57. [57] Qamar, A., Bhatt, D.L., Anticoagulation therapy: balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol 11:4 (2015), 200–202.
58. [58] Chan, K.E., Edelman, E.R., Wenger, J.B., et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131:11 (2015), 972–979.
59. [59] De Vriese, A.S., Caluwé, R., Bailleul, E., et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 66:1 (2015), 91–98.
60. [60] Wang, X., Tirucherai, G., Marbury, T.C., et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol, 2015, 10.1002/jcph.628 [Epub ahead of print].
61. [61] Parasrampuria, D.A., Marbury, T., Matsushima, N., et al. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost 113:4 (2015), 719–727.
62. [62] Liesenfeld, K.H., Clemens, A., Kreuzer, J., et al. Dabigatran treatment simulation in patients undergoing maintenance haemodialysis. Thromb Haemost, 115(3), 2015 [Epub ahead of print].
63. [63] Yao, Y., Yao, J., Radparvar, M., et al. Reducing Jagged 1 and 2 levels prevents cerebral arteriovenous malformations in matrix Gla protein deficiency. Proc Natl Acad Sci U S A 110:47 (2013), 19071–19076.
64. [64] Schurgers, L.J., Spronk, H.M., Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. Thromb Haemost 112:5 (2014), 909–917.
65. [65] Caluwé R, Pyfferoen L, De Boeck K, De Vriese AS. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kidney J 2016 [in press].
66. [66] Sarich, T.C., Seltzer, J.H., Berkowitz, S.D., et al. Novel oral anticoagulants and reversal agents: considerations for clinical development. Am Heart J 169:6 (2015), 751–757.
67. [67] Ansell, J.E., Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolysis 41:2 (2016), 248–252.
68. [68] Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:14 (2011), 1573–1579.
69. [69] Holmes, D.R. Jr., Doshi, S.K., Kar, S., et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65:24 (2015), 2614–2623.